NewAmsterdam Pharma (NASDAQ:NAMS) Director Sells $40,512.00 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director John Smither sold 1,600 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $25.32, for a total value of $40,512.00. Following the transaction, the director owned 8,760 shares in the company, valued at approximately $221,803.20. The trade was a 15.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $22.80 on Friday. The company has a market capitalization of $2.73 billion, a P/E ratio of -10.56 and a beta of 0.09. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $21.23 and a fifty-two week high of $42.21. The stock has a 50 day moving average price of $28.60 and a two-hundred day moving average price of $31.22.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%.The firm had revenue of $3.70 million during the quarter, compared to the consensus estimate of $2.83 million. As a group, equities analysts predict that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current year.

Analysts Set New Price Targets

NAMS has been the topic of a number of analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $45.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. BMO Capital Markets started coverage on NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an “outperform” rating and a $58.00 target price on the stock. Royal Bank Of Canada reduced their price target on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $52.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $49.73.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Engineers Gate Manager LP purchased a new stake in shares of NewAmsterdam Pharma in the 2nd quarter worth about $662,000. Squarepoint Ops LLC increased its position in shares of NewAmsterdam Pharma by 113.9% during the second quarter. Squarepoint Ops LLC now owns 92,026 shares of the company’s stock valued at $3,119,000 after buying an additional 49,005 shares during the period. Arizona State Retirement System lifted its holdings in NewAmsterdam Pharma by 34.6% in the second quarter. Arizona State Retirement System now owns 16,656 shares of the company’s stock worth $564,000 after buying an additional 4,281 shares during the period. California State Teachers Retirement System lifted its holdings in NewAmsterdam Pharma by 4,105.5% in the second quarter. California State Teachers Retirement System now owns 2,284,796 shares of the company’s stock worth $77,432,000 after buying an additional 2,230,467 shares during the period. Finally, Frazier Life Sciences Management L.P. boosted its position in NewAmsterdam Pharma by 6.8% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock valued at $613,033,000 after acquiring an additional 1,145,128 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly conditions involving elevated cholesterol and residual cardiovascular risk. The company’s lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve other lipid parameters.

Obicetrapib has been evaluated in several clinical studies, including the Phase 3 BROADWAY trial, for patients whose cholesterol levels remain inadequately controlled despite the use of existing lipid-lowering treatments.